Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2000-Year of the Biotechs! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (419)	2/29/2000 8:32:00 PM
From: Arthur Radley	Read Replies (3) \| Respond to of 1142

With today's close, it ends two months for my 2000 biotech selections....now up 120% YTD. 6 of 10 are triple digit gainers and only one loser..USON. Looking at my 1999 picks, the 14 month gain is 362%, with GLGC up a mere 1889%. Now if this performance doesn't support "luck" and the need for diversification, I don't know what does. I know we have talked "udder-nonsense" about NABI, but with a "lets suppose" scenario, given that they have several products in the pipeline and each addressing a huge market potential....here is a company with what may be construed as a current steady revenue stream and "maybe" on the verge of getting FDA approval within a year, just think what can be brought to the bottom-line for a product that might generate $500,000,000 in new revenue...remembering they have products now that cover their operating expenses and give them a profit. Do the numbers! Is NABI a mere $11 stock?